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ABSTRACT
Aim of the study. The 4C Mortality Score was created to predict mortality in hospitalised patients with COVID-19 and has to 
date been evaluated only in respiratory system disorders. The aim of this study was to investigate its application in patients with 
COVID-19-associated acute ischaemic stroke (AIS). 
Clinical rationale for study. COVID-19 is a risk factor for AIS. COVID-19-associated AIS results in higher mortality and worse 
functional outcome. Predictors of functional outcome in COVID-19-associated AIS are required. 
Materials and methods. This was a retrospective observational study of patients with AIS hospitalised in seven neurological 
wards in Małopolska Voivodship (Poland) between August and December 2020. We gathered data concerning the patients’ 
age, sex, presence of cardiovascular risk factors, type of treatment received, and the presence of stroke-associated infections 
(including pneumonia, urinary tract infection and infection of unknown source). We calculated 4C Mortality Score at stroke 
onset, and investigated whether there was a correlation with neurological deficit measured using the National Health Institute 
Stroke Scale (NIHSS) and functional outcome assessed using the modified Rankin Scale (mRS) at discharge. 
Results. The study included 52 patients with COVID-19-associated AIS. The 4C Mortality Score at stroke onset correlated with 
mRS (rs = 0.565, p < 0.01) at discharge. There was also a statistically significant difference in the mean 4C Mortality Score between 
patients who died and patients who survived the stroke (13.08 ± 2.71 vs. 9.85 ± 3.47, p = 0.04).
Conclusions and clinical implications. 4C Mortality Score predicts functional outcome at discharge in COVID-19-associated 
AIS patients. 
Key words: acute ischaemic stroke, COVID-19, 4C Mortality Score, modified Rankin Scale
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Introduction
As the COVID-19 pandemic caused by severe acute respirato-
ry syndrome coronavirus 2 (SARS-CoV-2) spread across the globe, 
researchers found growing evidence that several neurological 
conditions, including stroke, are associated with the disease [1]. 
A recent systematic review and meta-analysis has shown 
that acute cerebrovascular disease occurs in about 1.4% of all 
COVID-19 patients (ranging from 0.4% to 8.1% in different 
observational cohort studies) [2]. Acute ischaemic stroke 
(AIS) is the most common cerebrovascular complication of 
SARS-CoV-2 infection, but cases of COVID-19-associated 
haemorrhagic stroke and cerebral venous thrombosis have 
also been described in the literature [3, 4].
SARS-CoV-2 infection is proven to be an independent risk fac-
tor for AIS [5]. The suggested mechanisms in which SARS-CoV-2 
increases the risk of AIS are hypercoagulation, vasculitis and 
cardiomyopathy. Various laboratory markers of coagulopathy are 
found in patients with COVID-19, including elevated D-dimer 
levels and abnormalities in prothrombin time, platelet count or 
fibrinogen level; the presence of antiphospholipid antibodies has 
been detected in some patients, although their impact remains 
uncertain. Because angiotensin-converting enzyme 2 (ACE2) 
receptors, through which SARS-CoV2 enters the cells, are also 
present in the vascular endothelium, the virus can affect them 
causing lymphocytic endothelitis. Cardiomyopathy can be 
a direct effect of viral infection or can occur due to concomitant 
inflammation or hypoxia [6, 7]. Recent studies show that cases 
of AIS in patients with COVID-19 are more severe at onset [8] 
and result in higher mortality and worse functional outcome [9]. 
The 4C Mortality Score is a validated tool for predicting 
mortality in hospitalised patients with COVID-19 [10], but no 
studies have been performed thus far to assess its application 
in patients with COVID-19-associated AIS.
Clinical rationale for study
The aim of this study was to determine whether 4C Mor-
tality Score calculated at the onset of COVID-19-associated 
AIS could be a predictor of in-hospital death, and whether it 
correlated with neurological deficit and functional outcome 
at discharge. As SARS-CoV-2 is highly infectious and spreads 
quickly across different communities, the coming months may 
increase the burden of COVID-19-associated ischaemic stroke 
cases, meaning that there is an urgent need for research on 
prognostic tools in AIS patients.
Materials and methods
In this retrospective observational study, we analysed the 
medical documentation of patients diagnosed with stroke who 
were hospitalised in seven neurological wards in five cities 
in Małopolska Voivodship (Poland) between 14 August and 
16 December 2020.
The study included patients with AIS associated with 
COVID-19 infection, confirmed by detecting SARS-CoV-2 
RNA by reverse transcription polymerase chain reaction 
(RT-PCR) from a nasopharyngeal swab. 
We considered AIS to be associated with COVID-19 
in three cases:
1. AIS in a patient with ongoing symptomatic COVID-19 in-
fection confirmed before admission
2. AIS in a patient without symptoms of infection with a posi-
tive SARS-CoV-2 test on admission
3. AIS in a patient with a positive SARS-CoV-2 test obtained 
during hospitalisation in the stroke unit with no potential 
source of infection on that ward. 
The 4C Mortality Score was calculated on admission for 
each patient. This score ranges from 0 to a possible 21 points 
and it includes eight parameters: age, gender, number of co-
morbidities, peripheral oxygen saturation, respiratory rate, 
level of consciousness (assessed using the Glasgow Coma 
Scale) and results of laboratory tests: serum urea and C-reac-
tive protein levels [10]. 
Each patient was followed according to the standard proto-
col of the Krakow Stroke Data Bank, a single-centre registry of 
clinical, radiological and genetic data of hospitalised patients 
with AIS. For the purposes of this study, we analysed the 
presence of cardiovascular risk factors (Tab. 1) and concomi-
tant stroke-associated infections requiring antibiotic therapy 
including pneumonia, urinary tract infection and infections 
of unknown source. We also noted the type of treatment i.e. 
intravenous thrombolysis (IVT), mechanical thrombectomy 
(MT), or no reperfusion therapy. We collected data concerning 
in-hospital mortality, neurological deficit measured in the 
National Institute of Health Stroke Scale (NIHSS) at discharge, 
Table 1. Frequency of cardiovascular risk factors and stroke-associated infec-
tions requiring antibiotic therapy in patients with COVID-19-associated AIS
Cardiovascular risk factor N (%)
Arterial hypertension 43/52 (83%)
Diabetes mellitus 19/52 (37%)
Atrial fibrillation 19/52 (37%)
Coronary artery disease 16/52 (31%)
Overweight/obesity 12/52 (23%)
History of stroke/TIA 9/52 (17%)
Dyslipidemia 9/52 (17%)
History of smoking 9/52 (17%)
Peripheral arterial disease 8/52 (15%)
Carotid artery atherosclerosis 30/40 (75%)




Pneumonia + urinary tract infection 4/52 (8%)
Infection of unknown source 9/52 (17%)
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4C Morality Score at stroke onset
rs = 0.565, p < 0.1
and functional outcome at discharge assessed with the mod-
ified Rankin Scale (mRS). 
The data we collected was put into a database and ana-
lysed using a PS Imago Pro 6.0 program. Categorical data was 
presented as counts and percentages, and continuous data as 
mean and standard deviation (SD) or median and interquartile 
range (IQR). Continuous variables were tested for normality 
using a Shapiro-Wilk test and compared between groups by 
a Mann-Whitney U test. The correlations between continuous 
variables were assessed using Spearman’s rank-order correla-
tion. A p-value of less than 0.05 (two-sided) was considered 
to be statistically significant. 
This study was conducted in accordance with the Decla-
ration of Helsinki and approved by the Bioethics Committee 
of the District Medical Council in Krakow (opinion number 
143/KBL/OIL/2020).
Results
We identified 60 patients with COVID-19-associated 
stroke: 54 (90%) with AIS, five (8%) with haemorrhagic stroke, 
and one (2%) with cerebral venous thrombosis. Seventeen 
(31%) patients with COVID-19-associated AIS received rep-
erfusion therapy: 12 (22%) were treated with IVT, two (3.5%) 
with MT, and three (5.5%) with both methods. 
In one patient with AIS there was no follow-up available 
regarding neurological outcome because they had been trans-
ferred to another hospital. In one patient calculation of 4C 
Mortality Score at stroke onset was impossible because they 
had been hospitalised in another centre and the documenta-
tion data was incomplete. Therefore, the final analysis included 
52 patients with COVID-19-associated AIS.
The patients were aged 49 to 97 years with a mean age 
of 75 (SD = 10.8). 32 of them (61.5%) were male. Forty-six 
patients (88%) had at least two concomitant cardiovascular 
risk factors. The most common risk factor was arterial hyper-
tension (N = 43, 83%) (Tab. 1). The presence of carotid artery 
atherosclerosis could be assessed in 40 patients (in others the 
diagnostics of stroke causes was performed after discharge 
from a COVID ward, and they were lost to follow-up), and it 
was present in 30 (75%) of those 40 patients. 
A concomitant infection requiring antibiotic use was 
present in 30 (58%) patients: pneumonia in 17 patients (33%), 
both pneumonia and urinary tract infection in four (8%), 
and nine patients (17%) received antibiotics due to infection 
of unknown source. Seven (13%) patients were diagnosed 
with viral pneumonia due to COVID-19 and did not receive 
antibiotic therapy. 
The 4C Mortality Score at the onset of stroke varied from 
3 to 20 points with a median of 11 (IQR = 4). 
The mortality rate in our group was 23% (N = 12). There 
was a significant difference in the mean 4C Mortality Score 
between patients who died and patients who survived the 
stroke (13.08 ± 2.71 vs. 9.85 ± 3.47, p = 0.04).
There was a statistically significant (p < 0.01) moderate 
positive correlation between 4C Mortality Score and the 
in-hospital functional outcome after stroke assessed with 
mRS (Spearman’s Rank Correlation Coefficient = 0.565). For 
a scatterplot showing results of mRS at discharge in patients 
with different 4C Mortality Score results at onset, see Figure 1. 
The correlation between 4C Mortality Score and the neuro-
logical deficit at discharge measured using the NIHSS scale was 
also statistically significant (p = 0.038) but weak (Spearman’s 
Rank Correlation Coefficient = 0.329).
Discussion
Our study is the first to assess the significance of 4C 
Mortality Score in patients with COVID-19-related AIS. 
The score was created to predict mortality in hospitalised 
patients with COVID-19 [10] and further studies suggest that 
it could be applied to other respiratory system infections [12]. 
Our study shows that in the specific group of patients with 
COVID-19-associated AIS, who are in danger of not only 
death but also lifelong disability, 4C Mortality Score at onset 
could be a predictor of functional outcome after stroke. What’s 
Figure 1. Scatterplot showing results of mRS at discharge in patients with different 4C Mortality Score results at stroke onset with trendline
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more, patients who died of COVID-19-associated AIS had 
a statistically higher 4C Mortality Score at onset than those 
who survived. 
A case definition of COVID-19-associated stroke was 
recently proposed [13]. All of the patients included in this 
study fulfilled both major criteria of this definition i.e. 
clinical and neuroradiological evidence of acute stroke and 
SARS-CoV-2 detection by PCR testing. Twelve patients (23%) 
fulfilled two minor criteria (allowing us to diagnose probable 
COVID-19-associated stroke) and 29 (56%) fulfilled one minor 
criterion (allowing us to diagnose possible COVID-19-associ-
ated stroke). However, a full assessment of minor criteria was 
in some cases impossible because the levels of D-dimers and 
lactate dehydrogenase were not routinely assessed in some 
hospitals and information concerning mild infection symp-
toms preceding the stroke could be missing from the source 
medical documentation. 
Moreover, the minor criteria do not cover those patients 
who were asymptomatic during onset of the stroke (but tested 
positive for COVID-19 at admission) or those who tested 
positive a few days after developing stroke symptoms while 
being hospitalised (we included those patients in the study if 
there was no proof of an in-hospital epidemiological outbreak, 
assuming that the stroke may have occurred during the ‘win-
dow period’ for COVID-19) [14]. We combined AIS patients 
with symptomatic and asymptomatic SARS-CoV-2 infection 
patients in a unified study group to reflect the real-life clinical 
diversity of COVID-19-associated AIS. 
Our study has some important limitations. Firstly, it was 
of retrospective character and our observations need to be 
confirmed by prospective studies in larger cohorts of patients. 
Secondly, we did not analyse the impact of other factors (such 
as the type of reperfusion therapy received or the physical re-
habilitation of the patient). Thirdly, the assessment of Glasgow 
Coma Scale (GCS) may be flawed in patients with aphasia, 
thus modifying the result of 4C Mortality Score. However, as 
the Score does not require a specific result of GCS, but only 
information if the score was 15 points or less, in patients with 
aphasia we assessed only the quantitative disturbances of 
consciousness, whereas in patients without aphasia we could 
fully assess the GCS score. Fourthly, in some cases it is possible 
that some of the 4C Mortality Score components (such as low 
GCS score) were positive due to stroke, rather than due to the 
infection itself, thus impacting upon our results.
Clinical implications/future directions
4C Mortality Score predicts functional outcome at dis-
charge in COVID-19-associated AIS patients, making it 
potentially a promising prognostic tool. However, further 
prospective studies are needed to confirm our observations. 
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